reports
Lumos Pharma and Double Point Ventures Announce Successful Completion ...
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable t...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
MYE MYERS INDUSTRIES INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
LTRX LANTRONIX INC.
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
BRKR BRUKER CORPORATION
AXSM AXSOME THERAPEUTICS
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
ISTR INVESTAR HOLD
FRD FRIEDMAN INDUSTRIES INC.
SACH SACHEM CAPITAL
MBIN MERCHANTS BANCORP
LILA LIBERTY LATIN AMERICA A
FF FIRST MINING GOLD
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
FBRX FORTE BIOSCIENCES INC
TFC TRUIST FINANCIAL CORP
ONEW ONEWATER MARINE
ARRY ARRAY TECHNOLOGIES
SSSS SUTTER ROCK CAPITAL CORP.
ABCL ABCELLERA BIOLOGICS
CSU CAPITAL SENIOR LIVING
IMNM IMMUNOME
GRNT GRANIT SKOPKE
OSCR OSCAR HEALTH
WOLF WOLFSPEED INC
CLVT CLARIVATE PLC
ZETA ZETA GLOBAL HLDGS CORP
RWAY RUNWAY GROWTH FINANCE CORP
ANTX AN2 THERAPEUTICS INC
CGBD TCG BDC
NXGL INC.
HR NEXGEL INC
CARV HEALTHCARE TRUST OF AMERICA INC.
PFHC CARVER BANCORP INC
EP PROFRAC HLDG CORP
CATX EMPIRE PETROLEUM CORP
ASMB PERSPECTIVE THERAPEUTICS
DC INC.
FGF ASSEMBLY BIOSCIENCES INC
AGFY DAKOTA GOLD CORP.
FG FINANCIAL GROUP
INC.
AGRIFY CORPORATION
- Jonathan Moreland
RMAX RE/MAX HOLDINGS INC.
PSEC PROSPECT CAPITAL CORPORATION
PPSI PIONEER POWER SOLUTIONS
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ANGI ANGI INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MBIN MERCHANTS BANCORP
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
BDSX BIODESIX
CSU CAPITAL SENIOR LIVING
MODV MODIVCARE INC
GRNT GRANIT SKOPKE
UAN CVR PARTNERS LP
INBX INHIBRX
OSCR INC.
WOLF OSCAR HEALTH
CLVT WOLFSPEED INC
ZETA CLARIVATE PLC
RWAY ZETA GLOBAL HLDGS CORP
CGBD RUNWAY GROWTH FINANCE CORP
NXGL TCG BDC
BIGZ INC.
DOUG NEXGEL INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
EP DOUGLAS ELLIMAN INC
MIO WK KELLOGG CO
MDRR EMPIRE PETROLEUM CORP
BNTC PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
FGF BENITEC BIOPHARMA INC
EATON VANCE INSD CALIF MUN BD FD
FG FINANCIAL GROUP
INC.
- Jonathan Moreland
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MBIN MERCHANTS BANCORP
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
FBRX FORTE BIOSCIENCES INC
BDSX BIODESIX
INBX INHIBRX
OSCR INC.
CLVT OSCAR HEALTH
RWAY CLARIVATE PLC
NXGL RUNWAY GROWTH FINANCE CORP
HR NEXGEL INC
DC HEALTHCARE TRUST OF AMERICA INC.
DAKOTA GOLD CORP.
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sust...
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the , or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. “The new analyses and updated data from our Phase 2 OraGrow...
- Jonathan Moreland
PPSI PIONEER POWER SOLUTIONS
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SMRT SMARTSPACE SOFTWARE
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
UAN CVR PARTNERS LP
OSCR OSCAR HEALTH
ZETA ZETA GLOBAL HLDGS CORP
BGS B&G FOODS
EP INC.
MIO EMPIRE PETROLEUM CORP
MDRR PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
ACMR EATON VANCE INSD CALIF MUN BD FD
A.C. MOORE ARTS & CRAFTS
INC.
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
SATS ECHOSTAR CORPORATION CLASS A
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
KVHI KVH INDUSTRIES INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
GDOT CHART INDUSTRIES INC.
EXAS GREEN DOT CORPORATION CLASS A
CROX EXACT SCIENCES CORPORATION
CNC CROCS INC.
AGCO CENTENE CORPORATION
AVNW AGCO CORPORATION
ENPH AVIAT NETWORKS
HTLD ENPHASE ENERGY INC.
ZOM HEARTLAND EXPRESS INC.
DMLP ZOMEDICA PHARMACEUTICALS CORP
MAV DORCHESTER MINERALS L.P.
HLNE PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR HAMILTON LANE INCORPORATED CLASS A
MHI SLEEP NUMBER CORPORATION
GNL PIONEER MUNICIPAL HIGH INCOME TRUST
BBDC GALEY & LORD INC.
CLDX BARINGS BDC INC.
ENX CELLDEX THERAPEUTICS INC.
ADV EATON VANCE NEW YORK MUNICIPAL BOND FUND
HPK ADVANTAGE SOLUTIONS INC (A)
MRVI HIGHPEAK ENERGY INC (A)
OPCH MARAVAI LIFESCIENCES HOLDINGS
MODV OPTION CARE HEALTH INC
DCOM MODIVCARE INC
UAN DIME COMMUNITY BANCSHARES
PFBX INC.
OSCR CVR PARTNERS LP
BGS PEOPLES FINANCIAL CORP. (MISSISSIPPI)
WBD OSCAR HEALTH
TCBX B&G FOODS
BIGZ INC.
RXO_w WARNER BROS. DISCOVERY INC.
VANI THIRD COAST BANCSHARES INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
DBD RXO INC
MIO VIVANI MEDICAL INC
WPC WK KELLOGG CO
EVM DIEBOLD NIXDORF INCORPORATED
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
W. P. CAREY AND CO. LLC
EATON VANCE INSD CALIF MUN BD FD
- Jonathan Moreland
KVHI KVH INDUSTRIES INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
EXAS EXACT SCIENCES CORPORATION
CNC CENTENE CORPORATION
HLNE HAMILTON LANE INCORPORATED CLASS A
SNBR SLEEP NUMBER CORPORATION
GNL GALEY & LORD INC.
ADV ADVANTAGE SOLUTIONS INC (A)
OPCH OPTION CARE HEALTH INC
UAN CVR PARTNERS LP
OSCR OSCAR HEALTH
BGS B&G FOODS
TCBX INC.
VANI THIRD COAST BANCSHARES INC
GRNT VIVANI MEDICAL INC
SES GRANITE RIDGE RESOURCES INC
SES AI CORPORATION
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at...
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024 AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the , or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK. Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Defi...
Lumos Pharma Enters into Definitive Merger Agreement with Double Point...
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHD AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the Company has entered into a definitive merger agreement, dated October 2...
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the ...
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the , or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for...
- Adrian Loh Tzum Yung
- Damon Shen
- Desmond Chong Chee Wai
- Jack Lai Yuan Khai
- Jieqi Liu
- Kenny Yong Hui Lim
- Philip Wong
- Stevanus Juanda
- Tham Mun Hon
- Thanawat Thangchadakorn
Regional Morning Meeting Notes: Wednesday, September 25, 2024
GREATER CHINA Strategy PBOC Turns On The Tap The PBOC announced a series of easing measures on Tuesday. INDONESIA Update Astra International (ASII IJ/BUY/Rp5,275/Target: Rp5,800) About 70% of car and motorcycle sales to benefit from rate cut. Upgrade to BUY. MALAYSIA Results MyNews Holdings (MNHB MK/SELL/RM0.60/Target: RM0.52) 3QFY24: Results improved sequentially but disappointed consensus expectations. Valuations...
BBL BANGKOK BANK PUBLIC COMPANY LIMITED
TISCO TISCO FINANCIAL GROUP
KBANK KASIKORNBANK PUBLIC CO. LTD.
SCB SIAM COMMERCIAL BANK PUBLIC COMPANY LIMITED
ASII PT ASTRA INTERNATIONAL TBK
6493 TTBIO
VSI V.S. INDUSTRY BERHAD
MNHB MYNEWS HOLDINGS BHD
KTB KONTOOR BRANDS
SCI SCI E&C
TSVT 2SEVENTY BIO INC
DFI DFI RETAIL GROUP HOLDINGS LIMITED
Z29 029 GROUP SE
Lumos Pharma Announces Abstract Accepted for Presentation at September...
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024 AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile. Abstract Presentation: Friday, September 13th – E-poster Session ...
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Inve...
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th. H.C. Wainwright 26th Annual Global Investment Conference: September 9th – 11th Ti...
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provide...
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 3...
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provi...
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024 AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared re...
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Pres...
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the , held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024. “The new analyses of data from our OraGrowtH212 Trial further characterized LUM-201’s unique ability to augment the nat...
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 202...
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the , to be held in Boston, MA June 1-4, 2024. Poster Session P069 – Monday June 3, 12:00-1:30 PM ET : Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Ho...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Re...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therap...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provid...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.